Zacks Small-Cap Research
Sponsored – Impartial – Comprehensive

August 17, 2026
John D. Vandermosten, CFA
312-265-9588 / jvandermosten@zacks.com

scr.zacks.com
101 N. Wacker Drive, Chicago, IL 60606

Cardiff Oncology, Inc. (CRDF: NASDAQ)

CRDF: Second Quarter Earnings

Our valuation relies on a DCF model and a 15% discount rate applied to our cash flow estimates. Additionally, we apply a success probability of 50% to the onvansertib program in metastatic colorectal cancer (mCRC). The likelihood recognizes regulatory and commercialization risks. The model includes contributions from the United States and the developed world.

Current Price (8/14/2026)	$0.96
Valuation	**$7.50**

OUTLOOK

Cardiff is a clinical-stage, oncology-focused biotechnology company developing onvansertib against solid tumors including subsets of colorectal (CRC), pancreatic, lung and breast cancers. The company's primary indication is first line metastatic CRC in patients with RAS mutations.

Onvansertib is an oral Polo-like kinase 1 (PLK1)-selective inhibitor that synergizes with bevacizumab & various chemotherapy regimens. It is the subject of a Ph2 dose confirmation trial and is anticipated to begin a Ph3 study in 2027. PLK1 plays a central role in cell-cycle regulation, and its dysregulation can permit uncontrolled mitosis. When inhibited, the cell cycle can be arrested & synthetic lethality can occur especially in combination with other anti-angiogenic agents and chemotherapy.

While the lead indication addresses metastatic CRC, onvansertib has potential in other cancers. Future studies may explore combinations with chemotherapy, checkpoint inhibitors, and PARP inhibitors.

SUMMARY DATA

52-Week High	**$3.31**
52-Week Low	**$0.76**
One-Year Return (%)	**-60.5**
Beta	**1.5**
Average Daily Volume (sh)	**1,565,540**
Shares Outstanding (mil)	**77.8**
Market Capitalization ($mil)	**74.7**
Short Interest Ratio (days)	**7.5**
Institutional Ownership (%)	**21.3**
Insider Ownership (%)	**6.1**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/A**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**
P/E using TTM EPS	**N/A**
P/E using 2026 Estimate	**N/A**
P/E using 2027 Estimate	**N/A**
Zacks Rank	**N/A**

Risk Level	**Above Average**
Type of Stock	**Small-Growth**
Industry	**Med-Biomed/Gene**

ZACKS ESTIMATES

Revenue

(In millions of US$)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2025	$0.1 A	$0.1 A	$0.1 A	$0.2 A	$0.6 A
2026	$0.0 A	$0.1 A	$0.1 E	$0.2 E	$0.4 E
2027					$0.7 E
2028					$0.8 E

Earnings per Share

	Q1	Q2	Q3	Q4	Year
2025	-$0.20 A	-$0.21 A	-$0.17 A	-$0.11 A	-$0.69 A
2026	-$0.18 A	-$0.14 A	-$0.15 E	-$0.17 E	-$0.64 E
2027					-$0.57 E
2028					-$0.55 E

WHAT'S NEW

2Q:26 Financial Results

Cardiff Oncology, Inc. (NASDAQ: CRDF) reported second quarter 2026 financial and operational results in a press release and Form 10-Q filing with the SEC on August 11th, 2026. The company highlighted the Phase II data presented at ASCO at the end of May and shared its plans to initiate its pivotal onvansertib study in 1Q:27. Additional capital will be required to start the trial. Management also pointed to the $10 million registered direct offering that was completed in mid-July which extends the cash runway. Regarding the Nerviano (NMS) dispute, in June Cardiff filed a motion for preliminary injunction requesting a halt to the termination which was opposed by NMS. The injunction is awaiting decision while the two parties are conducting an Early Neutral Evaluation. In the meantime, Cardiff is advancing the onvansertib program towards the pivotal Phase III CRDF-005 study and has updated survival data for the CRDF-004 study as of late June.

For the three-month period ended June 30th, 2026 Cardiff reported revenues of $104,000 and operating expense of $9.7 million. Loss per share was $0.14. Operating expenses fell 35% as lower Research and Development (R&D) expenses were partially offset by higher General and Administrative (G&A) expenses. For the quarter ended June 30th, 2026 and versus the same prior quarterly period:

- Revenue of $104,000 compared to $121,000 and represent Cardiff's sales-based and usage-based royalties on assets unrelated to onvansertib;
- Research and development expenses totaled $5.9 million, down 49% from $11.6 million, predominantly due to a reduction in clinical trial expenses related to CRDF-004. Salaries, stock-based compensation and facilities costs also fell;
- Selling, General & Administrative expenses were $3.8 million, up 15% from $3.3 million. Increases in outside services and professional fees related to the Nerviano dispute, salaries and facilities costs were partially offset by a decline in stock-based compensation;
- Net interest income of $382,000 was down compared with prior period amounts due to reduced interest income on lower cash levels. Other income of $1,000 compared to other expense of $1,000;
- Net loss was $9.2 million vs a net loss of $13.9 million or $0.14 and $0.21 per share, respectively.

As of June 30th, 2026, cash, equivalents and short-term investments totaled $34.5 million. This amount compares to the $58.3 million balance in cash held at the end of 2025. Cash burn for the first six months of 2026 was $24.1 million versus $21.1 million. Following the end of the quarter, Cardiff executed a $10 million capital raise. Cash is expected to support operating activities into 3Q:27. The company will require additional capital to fund and initiate the CRDF-005 Phase III registrational study.

Updated Results from CRDF-004

Cardiff Oncology, Inc. (NASDAQ: CRDF) presented interim data from its CRDF-004 trial at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The event took place from May 29th to June 2nd 2026. The oral presentation was entitled Onvansertib plus standard-of-care chemotherapy plus bevacizumab in first-line RAS-mutated metastatic colorectal cancer (mCRC): Interim results from the phase 2 randomized CRDF-004 trial. It reiterated topline data from the Phase II CRDF-004 trial highlighting 72.2% overall response rate (ORR)[1] for the 30 mg + FOLFIRI[2] + bevacizumab (bev) arm compared to 42.1% ORR in the control arm, which consisted of FOLFIRI + bev. Data was presented by Heinz-Josef Lenz, MD in a rapid oral session.

Dr. Lenz also participated in Cardiff's conference call held on June 3rd along with another key opinion leader (KOL) Josep Tabernero, MD, PhD. Company management was represented by CEO Mani Mohindru, PhD. The call included a presentation which summarized the findings as of the March 18th, 2026 cutoff. Nine of 36 patients in the Onvansertib + FOLFIRI/bev arm remained on treatment while only one patient remained on treatment in the FOLFIRI/bev arm. 14 patients remain on study treatment. Depth of response for the onvansertib group is also notable with seven of the onvansertib patients achieving near complete or complete responses compared to none in the control group.

[1] ORR reflects BICR - Blinded Independent Central Review
[2] FOLFIRI is a combination chemotherapy regimen that includes folinic acid, fluorouracil and irinotecan.

New data included breakdowns by subgroup showing consistent benefit in each for ORR and progression free survival (PFS). When the 30 mg onvansertib + FOLFOX[3] arm was compared to the FOLFOX arm, there was no meaningful benefit. Cardiff provided a rationale for the difference in performance between FOLFIRI and FOLFOX, acknowledging the multi-pronged impact on angiogenesis from irinotecan, onvansertib and bev.

Exhibit I – CRDF-004 Trial Details



Source: June 2026 Interim Results Presentation

Rationale for Onvansertib Synergy with FOLFIRI

The CRDF-004 data show improved performance for the FOLFIRI arms in both ORR and hazard ratio relative to the FOLFOX arm. During Cardiff's presentations, stakeholders have repeatedly sought an explanation for the difference between the two chemotherapy standards of care. In response, the Cardiff team developed a mechanistic rationale for onvansertib's synergy with FOLFIRI but not FOLFOX. They conclude that onvansertib and irinotecan both cause HIF1-α suppression which has anti-angiogenic effects. Irinotecan induces DNA damage primarily by targeting topoisomerase I, which is essential for relieving torsional strain. Onvansertib inhibits the DNA-repair pathway that is activated following irinotecan-induced DNA damage creating synergy between the two. FOLFOX is thought to be less effective because oxaliplatin has a low impact on HIF1-α suppression and no shared antiangiogenic effect.[4] Oxaliplatin-induced DNA damage uses nucleotide excision repair and excludes PLK1. Oxaliplatin acts as a platinum-based alkylating-like agent that directly binds to the DNA architecture, forming physical obstructions that block replication and transcription.

Exhibit II – Onvansertib-FOLFIRI Synergy Rationale



Source: June 2026 Interim Results Presentation / Irinotecan is a prodrug of SN38; HCT116 is a human colorectal cell line

[3] FOLFOX is a combination chemotherapy that includes folinic acid, fluorouracil and oxaliplatin.
[4] We reiterate that these are company-proposed, preclinical mechanistic hypotheses and not clinical proof.

CRDF-004 Data as of March 18th, 2026

CRDF-004 is ongoing and had not yet reached median PFS (mPFS) in either the 20 mg or 30 mg arms as of the March 18th, 2026 data cut. While ORR was unchanged from the previous update in February 2026, numerous hazard ratios were reported and the categories presented were not consistent between the January update and the June update making direct comparisons difficult.[5] We see the combined 30 mg + FOLFIRI/bev HR as the relevant number as this is the regimen that will be investigated in the pivotal trial. In January, the blinded independent central review (BICR) HR was reported as 0.38 for onvansertib 30 mg vs. FOLFIRI/bev. While still compelling, in June, the HR for this group was reported as 0.55 for the BICR assessment and 0.57 for the investigator assessment.[6] The confidence interval for both crossed 1, thwarting statistical significance, but an expected result given the small N.

The trend for mPFS was a consistent positive in both the January and June updates. For both period observations, mPFS had not yet been reached for either the 20 mg and 30 mg onvansertib + FOLFIRI/bev arms, signaling a durable benefit for a material portion of the population. This was consistent for both the BICR and investigator assessment approaches.

Exhibit III – CRDF-004 Progression Free Survival, Active vs. Control Arm



	FOLFIRI/bev + FOLFOX/bev	Onv (20 & 30mg) + FOLFIRI/bev
N	37	36
Median PFS	11.07	NR*
HR (95% CI)	0.44 (0.15, 1.25)	

	FOLFIRIbev + FOLFOX/bev	Onv (20 & 30mg) + FOLFIRI/bev
N	37	36
Median PFS	10.97	NR*
HR (95% CI)	0.53 (0.25, 1.15)	

Source: June 2026 Interim Results Presentation

Cardiff's presentation included several data breakdowns that examined the performance of the 30 mg onvansertib + FOLFIRI/bev group. In almost all categories (age, liver only disease, side of tumor, etc), the onvansertib group offered ORR and PFS benefits (slides 17 and 18). Toxicities were reviewed on slide 19. We focus on the 30 mg onvansertib arm +FOLFIRI/bev safety profile, which, in our opinion, was not materially different from the FOLFIRI control arm, especially when looking at Grade 3 or greater events. Cardiff noted that onvansertib showed no unexpected, overlapping or new toxicities when compared to the FOLFIRI or FOLFOX arms.

The CRDF-004 trial generated a 30% percentage point improvement in ORR in the 30 mg arm. As of the March 18th cutoff date, mPFS had not yet been reached, suggesting a favorable survival benefit of onvansertib. The main objective of CRDF-004 was to determine whether adding onvansertib to standard first-line therapy could improve outcomes in patients with RAS-mutated metastatic colorectal cancer, and to identify the best regimen to move into Phase III. CRDF-005 is the trial intended to formally test ORR and PFS with adequate statistical power.

CRDF-004 Data as of June 23rd, 2026

In its second quarter earnings release, Cardiff updated patient status as of June 23rd identifying 12 patients remaining on trial with 8 patients in the onvansertib + FOLFIRI/bev arms and one patient remaining on SoC. It did not disclose whether or not median PFS had been reached. We expect an update to come with additional details at a conference later this year.

[5] In Cardiff's presentation, the PFS HRs were combined then separated for BICR and Investigator Assessment, then combined and separated for the 20 and 30 mg doses. It did not provide a HR for the same population in both presentations, frustrating direct comparisons.

[6] Due to the low number of BICR progression events, Cardiff noted that it used a combined BICR/investigator approach for the PFS events and used the earliest date measured as a conservative estimate.

Nerviano Dispute

Earlier this year, Nerviano Medical Sciences sent written notice to Cardiff alleging that it was in a material breach of the onvansertib license agreement between the two. Brief details of the interaction were included in the 2025 Form 10-K. Nerviano attributed the breach to the failure of Cardiff to name a Nerviano employee as joint inventor for US patents 12,144,813 and 12,263,173. Cardiff maintains that there is no breach and that the agreement does not require Cardiff to name Nerviano employees on patents that have been developed exclusively by Cardiff. It seeks injunctive relief requiring Nerviano to continue performing under the agreement and for the court to declare that it did not breach the agreement. Details of the event are in a Form 8-K filed on May 19th, 2026. On May 27, 2026, Nerviano notified Cardiff that it was terminating the agreement. Cardiff asserted that the termination notice was legally ineffective, factually unsupported and procedurally improper, and that it would continue to perform under the agreement.

In an update provided in the second quarter 2026 Form 10-Q, Cardiff provided updates to the dispute with NMS. On June 10th, 2026, Cardiff requested that the District Court prohibit NMS from terminating the agreement and causing other interference. NMS opposed the request on July 17th and Cardiff replied in support of it on July 24th. The motion is fully briefed and awaiting decision. NMS answered the complaint and filed counterclaims on June 26th, asserting counterclaims for correction of inventorship, declaratory judgments of joint invention and termination, breach of contract, and breach of implied covenant of good faith and fair dealing. Cardiff moved to dismiss all counts except for NMS's counterclaim for a correction of inventorship on July 17th and also filed an amended complaint on July 17th, adding additional claims for breach of contract, unjust enrichment and unfair competition in violation of California Business & Professions Code § 17200 seeking monetary and other relief. Further discussion with management clarified that both parties' legal counsel have conducted Early Neutral Evaluation (ENE) as mandated by the court. The goal of ENE is to reduce the court's burden and find a solution with the help of a neutral expert. The ENE concluded on August 7th and the parties will meet with the judge on August 21st. It is our understanding that the court has not and will not take up the time-consuming effort of reviewing the case before hearing details from the ENE. This suggests that the earliest that the court might dismiss the matter may be in late August. Other options are also possible including a return to ENE, denial of injunctive relief among others.

The patent licensed by Nerviano has an expiry of May 2030 and it is likely that a full five years of patent term extension (PTE) will be allowed. With the PTE, the effective end of protection related to Nerviano's intellectual property is 2035. We believe that the wording in the original license arrangement will be key to the outcome. As equity analysts, we do not provide legal opinions and lack complete visibility into the patents' development; however, we can point investors to the language in the agreement dated March 13th, 2017 with Cardiff's predecessor Trovagene. The language states that Trovagene/Cardiff has entire rights to intellectual property it solely develops:

10.2 Ownership of Inventions. Subject to the terms hereof, including the licenses and other rights granted hereunder, all Inventions shall be owned as follows:

(a) Nerviano shall own the entire right, title and interest in and to all Inventions (including all patents and other intellectual property rights thereto) made solely by its employees or others acting on behalf of Nerviano (or solely by such persons and Third Parties performing work for Nerviano) in the performance of the Development Plan or other activities undertaken under this Agreement ("After-Developed Nerviano Inventions"). All After-Developed Nerviano Inventions will be included in the license and right granted under Article 3 above;

(b) ***Trovagene [now Cardiff] shall own the entire right, title and interest in and to all Inventions (including all patents and other intellectual property rights thereto) made solely by its employees or others acting on behalf of Trovagene (or solely by such persons and Third Parties performing work for Trovagene) in the performance of the Development Plan or other activities undertaken under this Agreement****;*

(c) The Parties shall jointly own all Joint Inventions (as defined below). Nerviano's rights in and to each Joint Invention (including all patent rights and other intellectual property rights to it) will be included in the license and rights granted under Article 2 above, and, subject to such license and rights, each Party may make, use, sell, keep, license or assign its interest in Joint Inventions and otherwise undertake all activities a sole owner might undertake with respect to such Joint Inventions, without the consent of and without accounting to the other Party. "Joint Inventions" means Inventions for which it is determined, in accordance with United States patent law, that both: (i) one or more employees, consultants or agents of Nerviano or any other persons obligated to assign such Invention to Nerviano; and (ii) one or more employees, consultants or agents of Trovagene or any other persons obligated to assign such Invention to Trovagene, are joint inventors.

AACR Poster

Cardiff presented a poster at the 2026 American Association for Cancer Research (AACR) Annual Meeting held in San Diego, California from April 17th to 22nd. The title of the poster is PLK1 inhibitor onvansertib potentiates the anti-tumor efficacy of trastuzumab deruxtecan (T-DXd) and reverses its resistance in therapy-resistant HER2-low breast cancer models. It summarized preclinical work that examined the combination of trastuzumab deruxtecan (T-DXd) (Enhertu) with onvansertib and its effect on patient-derived xenograft models. Tumor volumes were measured using monotherapy of T-DXd and onvansertib and the combination of the two compared with a control. The xenograft models consistently showed that the combination therapy limited and even reversed tumor growth.

The poster concluded that onvansertib enhances T-DXd efficacy and overcomes its resistance across triple negative breast cancer (TNBC) and hormone receptor positive (HR+) breast cancer models. The combination induces synergistic DNA damage and apoptosis. The authors claim that PLK1 inhibition offers a strategy to deepen and prolong T-DXd response in advanced HER2-low breast cancer resistant to first-line therapies.

Next Steps for Onvansertib

Following meetings with the FDA, Cardiff essentially finalized the design of the Phase III registrational trial for onvansertib. The trial is designated CRDF-005 and will evaluate 30 mg of onvansertib with FOLFIRI and bev vs. the standard of care of FOLFIRI/bev in first line RAS-mutated mCRC. In its investor presentation, management provided a preliminary trial design that seeks to enroll first line mCRC patients that are KRAS and NRAS positive presenting unresectable tumors. Dual primary endpoints are anticipated to be ORR and PFS with secondary endpoints of DoR and OS.

Exhibit IV – Preliminary Trial Design for CRDF-005, Onvansertib's Registrational Trial



Source: Cardiff May 2026 Corporate Presentation

The trial is expected to enroll approximately 640 patients and is designed with greater than 90% statistical power for its key efficacy endpoints, including PFS and ORR. The FDA has indicated the potential for accelerated approval based on ORR and durability of response. While Cardiff has received input from the FDA, the company is awaiting feedback from the European Medicines Agency (EMA). We anticipate a focus on raising capital in the near term and the CRDF-005 trial launch in 2027.

Company Pipeline

Exhibit V – Cardiff Pipeline

	Line of Therapy	Trial	IIT*	Ph1	Ph2	Ph3	Combination with:
mCRC (RAS-mut)	1st line	CRDF-004 (w/Pfizer)			randomized		FOLFIRI/bev and FOLFOX/bev
	2nd line	Ph 1b/2			completed		FOLFIRI/bev
CMML	2nd line	Ph 1	Mayo Clinic Rochester, Minnesota		expansion ongoing		None (monotherapy)
mPDAC	1st line	Ph 2	KU Medical Center				NALIRIFOX
	2nd line	Ph 2			completed		Nal-IRI/leucovorin/5-FU
SCLC	2nd line	Ph 2	University of Maryland				None (monotherapy)
TNBC	2nd line	Ph 2	Dana-Farber Cancer Institute				Paclitaxel

Source: Cardiff August 2026 Corporate Presentation

Milestones

- Topline release from CRDF-004 – January 27th, 2026
- Nerviano sends notice alleging material breach of onvansertib licensing agreement – February 2026
- Dr. Mani Mohindru appointed President and CEO – April 2026
- Meetings with FDA for Phase III trial design – April 2026
- Josh Muntner appointed as Chief Financial Officer – April 2026
- Ajay Aggarwal, MD, appointed as Chief Operating Officer – April 2026
- Onvansertib and trastuzumab poster presentation at AACR – April 2026
- Cardiff files suit against Nerviano disputing breach of license agreement – May 2026
- ASCO presentation of CRDF-004 data – June 2nd, 2026
- Webcast to discuss Phase II CRDF-004 data – June 3rd, 2026
- Jefferies Global Healthcare Conference Participation – June 4th, 2026
- CRDF-004 data cut – June 23rd, 2026
- Cardiff & NMS counsel meet with judge following ENE – August 21st, 2026
- Further details provided on Phase III and regulatory strategy – 2H:26
- Launch of Phase III onvansertib trial (CRDF-005) – 1Q:27

Summary

Cardiff reported second quarter earnings and outlined its plans for a 1Q:27 start to the Phase III onvansertib trial. The company is facing two important hurdles including the Nerviano dispute and the need to raise significant capital before CRDF-005 can begin. While these are substantial challenges, onvansertib's performance has been strong, generating an encouraging PFS trend relative to standard of care in the difficult RAS-mutated colorectal cancer population.

PROJECTED FINANCIALS

Cardiff Oncology, Inc. - Income Statement

Cardiff Oncology, Inc.	2025 A	Q1 A	Q2 A	Q3 E	Q4 E	2026 E	2027 E	2028 E
Total Revenues ($USD)	**$593**	**$41**	**$104**	**$140**	**$155**	**$440**	**$725**	**$750**
Research & Development	$35,329	$6,765	$5,915	$9,100	$10,850	$32,630	$47,520	$50,050
General & Administrative	$14,224	$6,126	$3,804	$3,450	$3,424	$16,804	$17,200	$17,650
Other Operational Items								
Income from Operations	($48,960)	($12,850)	($9,615)	($12,410)	($14,119)	($48,994)	($63,995)	($66,950)
Interest Income, net	$3,104	$506	$382	$400	$350	$1,638	$800	$310
Other Items	$5	($1)	$1	$0	$0	$0	$0	$0
Preferred Stock Dividend	($25)	($6)	($6)	($6)	($6)	($25)	($25)	($25)
Pre-Tax Income	($45,876)	($12,351)	($9,238)	($12,016)	($13,775)	($47,381)	($63,220)	($66,665)
Provision for Income Tax	$0	$0	$0	$0	$0	$0	$0	$0
Tax Rate								
Net Income	**($45,876)**	**($12,351)**	**($9,238)**	**($12,016)**	**($13,775)**	**($47,381)**	**($63,220)**	**($66,665)**
Net Margin								
Reported EPS	**($0.69)**	**($0.18)**	**($0.14)**	**($0.15)**	**($0.17)**	**($0.64)**	**($0.57)**	**($0.55)**
YOY Growth								
Basic Shares Outstanding	66,841	68,350	68,397	77,900	82,000	74,162	110,000	121,000

Source: Company Filing // Zacks Investment Research, Inc. Estimates

HISTORICAL STOCK PRICE

Cardiff Oncology, Inc. – Share Price Chart[7]



[7] Source: Zacks Research System.

DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, John Vandermosten, hereby certify that the views expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.

Zacks SCR has received compensation from the issuer directly or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.
SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.